Phathom Pharmaceuticals (PHAT) Stock Price Drops After Q3 Earnings Growth

Phathom Pharmaceuticals just released its Q3 2026 report and the headline is simple. The gastro‑focused biotech is growing revenue while still posting losses, yet the share price fell 7.7% to close at US$5.74. That is the sentiment gap investors need to understand.

Revenue reached US$84.7m for the quarter and management highlighted positive operating profit on a cash basis alongside positive operating cash flow. The equity market still reacted as if the risk story mattered more than those improvements, setting up a clash between emotion and the earnings detail that follows.

Like the revenue traction at Phathom Pharmaceuticals but uneasy about the ongoing losses and market volatility around the stock? Compare this setup with companies that pair resilient balance sheets with improving fundamentals in our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$84.7m vs. US$49.5m (up roughly 71% year on year)
• Net Loss (Q3 2026 vs Q3 2025): US$13.9m loss vs. US$30.0m loss (loss narrowed compared with prior year)
• Basic EPS (Q3 2026 vs Q3 2025): US$0.16 loss per share vs. US$0.41 loss per share (per share loss reduced year on year)
• Operating Profit ex Stock Based Compensation (Q3 2026): US$5.8m profit vs. US$17.6m loss in Q2 2026 net income (shift to a positive operating result on this cash basis)

Phathom is betting big on an “Access First” BlinkRx strategy. Ask Charlie what makes Phathom’s BlinkRx push so important.

Phathom Tests The Access First Bull Case

The bullish story depends on VOQUEZNA becoming a broad GERD franchise rather than a niche product for the sickest patients.

"The main thing that has to go right is that Phathom Pharmaceuticals reduces payer and office workflow friction enough for VOQUEZNA to move beyond the most severe GERD patients into broader, higher volume use without eroding its high gross margins."

Q3 hints at that shift starting. Covered VOQUEZNA prescriptions reached about 248,000, roughly 65% of total fills, and grew faster than cash pay scripts. Two straight quarters of operating profit on a cash basis plus positive operating cash flow indicate that the Access First push and BlinkRx focus are beginning to translate into real operating leverage for Phathom Pharmaceuticals, even as gross margin remains slightly below the long-term target.

The price and this Narrative do not agree. → Uncover what this Narrative says Phathom Pharmaceuticals is actually worth.

Bear Case On Phathom’s Access Friction Meets The Numbers

Bearish investors argue that Phathom Pharmaceuticals will struggle to turn VOQUEZNA demand into durable, self funding economics because payer hurdles and heavy discounts choke off net revenue and cash.

"Although Phathom Pharmaceuticals reports growing VOQUEZNA use among high-severity GERD patients, the cut to 2026 net revenue guidance to a range of $310 million to $325 million due to physician reluctance to work through access hurdles for less severe cases points to a risk that payer and workflow friction caps future script growth and restrains revenue and earnings."

Q3 keeps that fear alive. Covered scripts are growing faster than cash pay, yet the share price fell 7.7% and guidance is unchanged rather than raised. Gross to net is tracking in the mid 50s% and gross margin is below target after one off costs. Cash from operations is positive but modest relative to US$184.6m on the balance sheet, so self funding still looks early.

Hunt Disconnected Fundamentals Quietly

Phathom Pharmaceuticals recently showed that fundamentals and price can look very different in a single quarter. The real opportunity could sit in companies where that mismatch has not closed yet.

• Company 1 - 27% below our estimate - helps supply grid testing hardware utilities use as electrification and data centers strain aging transmission equipment.
• Company 2 - 37% below our estimate - uses recent acquisitions and lower cost deposits to reshape a niche lender into a broader, more efficient regional banking platform.
• Company 3 - 42% below our estimate - sells modular server racks that large buyers now prefer when rolling out massive AI and analytics capacity quickly.

That is three of the list. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com